CA2174608C - Dietary supplement for alleviating the symptoms associated with enlargement of the prostate gland - Google Patents
Dietary supplement for alleviating the symptoms associated with enlargement of the prostate glandInfo
- Publication number
- CA2174608C CA2174608C CA002174608A CA2174608A CA2174608C CA 2174608 C CA2174608 C CA 2174608C CA 002174608 A CA002174608 A CA 002174608A CA 2174608 A CA2174608 A CA 2174608A CA 2174608 C CA2174608 C CA 2174608C
- Authority
- CA
- Canada
- Prior art keywords
- weight
- composition
- amount
- dietary supplement
- enlargement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
A composition for a dietary supplement includes: 12.5 to 25% pumpkin seeds by weight; 1.875 to 18.75% extract of serenoa repens by weight; 6.25 to 2.5% pygeum africanum by weight; 3.125 to 6.25% zinc glycinate by weight; 3.125 to 9.375% magnesium by weight; and 9.375 to 18.75% vitamin E acetate by weight. The composition may further include Di- Tab, Syloid and magnesium stearate as excipients.
Description
DIETARY SUPPLEMENT FOR ALLEVIATING THE SYMPTOMS
ASSOCIATED WITH ENLAR(;~ OF THE PROSTATE GLAND
BACRGROUND OF THE lNvkNllON
Field of the Invention The present invention relates to a dietary supplement, and more particularly, to a dietary supplement for alleviating the symptoms associated with enlargement of the prostate gland.
Description of the Related Art It is well known that many disorders are the result of dietary deficiencies wherein the body is starved of certain vitamins, minerals and other natural elements. Other disorders are simply the result of aging. Disorders due to aging may result if the body produces too much or too little of certain enzymes or hormones, thereby affecting the body's metabolism. Some disorders can be treated or corrected by supplementing missing natural elements which are ordinarily not found in the average diet. Through the use of a daily supplement, supplying these missing vitamins and natural elements, the symptoms of various disorders may improve or disappear entirely.
In men, the prostate gland is the source of several common disorders including prostatitis and benign prostatic hypertrophy, wherein the prostrate gland becomes inflamed or enlarged. Benign prostatic hypertrophy (BPH) occurs naturally in most males over 50 years of age. At this age, the male body begins to transform testosterone (male sex hormone) into dihydroxytestosterone (DHT), at higher levels, within the prostate. This is primarily due to higher levels of the enzyme reductase which causes the conversion of testosterone to DHT. DHT has a tendency to bind to prostatic receptor cells which ultimately results in prostate enlargement. It is usually a benign condition and, thus, in some cases there is no need for surgery. However, enlargement of the prostate gland can cause many uncomfortable and annoying symptoms including:
difficulty in starting to urinate;
increased urge to urinate;
a weak or interrupted stream when urinating;
a feeling that you cannot empty your bladder completely;
a feeling of delay when you start to urinate;
a need to urinate often, especially at night; and frequent or continuous lower back pain.
Nearly 400,000 prostate surgical procedures are performed annually to treat enlarge prostates. Numerous laboratories are conducting research in an attempt to find a cure for BPH (benign prostatic hypertrophy). In 1992, several new drugs were introduced to the market which resulted in reductions of approximately 60%-70% of nicturia, 50% in diuria frequency, and 40% in post mictional residue.
However, some doctors have reported that as many as 15% of patients have complained of impotency after taking these drugs. Additionally, there are side effects which are noted by the FDA, as reported in the January, 1995 issue of U.S.
News and World Report.
There are natural elements which have known benefits in treating enlargement of the prostate gland and prostatitis.
Specifically, it is widely accepted in the field of medicine that zinc has positive effects in reducing an enlarged prostate (see "What Every Man Should Know About His Prostate,~ Monroe E. Greenberger, M.D. and Mary Ellen Siegel MSW, pages 96-105). However, studies have indicated that when zinc is administered orally, it is difficult to reach the prostatic tissue. Therefore, the prostate does not reap the full benefits of the zinc.
Other studies have shown that pygeum africanum extract has definite effects in reducing the size of the prostate (Please refer to Medical Treatment of Benign Prostatic Hypertrophy With the Pygeum Africanum Extract, n R.M. Scarpa, 21~4~Q~
R. Migliari, G. Campus, A. DeLisa, M. Sorgia, M. Usai, E.
Usai, Urology Clinic of the University of Cagliari).
Further, extensive studies carried out in Europe have established that saw palmetto (serenoa repens) effectively reduces the size of the enlarged prostate and restores function. The saw palmetto berry contains an oil composed of sterols and various saturated and unsaturated fatty acids. In Europe, and now in the United States, the purified fat soluble extract from the saw palmetto berry is used medicinally.
Another natural product known to have beneficial effects on the enlarged prostate is pumpkin seeds. While there are no significant medical studies, pumpkin seeds have been used as a folk remedy for centuries. In fact, it is believed that Hungarian gypsies, Ukrainians and Transylvanian's do not suffer from BPH because these cultures eat pumpkin seeds from childhood as part of their daily diet.
Presently, in the United States, most patients suffering from benign prostatic hypertrophy and prostatitis are treated with drugs such as Hytrin~ (Terazosin-HCI), manufactured by Abbott Laboratories, Proscar~, manufactured by Merck and Company, Inc., and Flutamide0. While these drugs have beneficial effects in treating BPH, they have known side effects, including impotency in men. More specifically, Proscar~ is known to be transmitted to females through semen during sexual intercourse, presenting a significant health risk to women who are or could become pregnant. Further, the FDA has reported that Hytrin~ may cause Prioprism, resulting in persistent, painful erections which can permanently damage the penis. The side effects of Flutamide~ include painful swelling of the man's breasts as well as nausea, vomiting and diarrhea.
Summary of the Invention The present invention is directed to a dietary supplement for alleviating the symptoms associated with enlargement of the prostate gland and inflammation of the prostate gland and comprising pumpkin seeds, zinc glycinate, extract of serenoa repens, pygeum africanum, magnesium and Vitamin E acetate. While some of these elements have known benefits to the prostate gland, as stated above, it has been found that when combined in accordance with determined proportionate ranges, the combined ingredients have synergistic effects on reduction of the size of the prostate gland, thereby providing more immediate and dramatic relief to those suffering from the symptoms associated with BPH and prostatitis, without the adverse side effects as experienced with the above-mentioned drugs. The efficacy of the composition was determined by monitoring various parameters including serum prostate-specific antigen (PSA) concentrations of patients over 90 day periods, nicturia, diuria, and urine flow rate. These results were compared to known results in past studies using only one element, or a sub-combination of elements of the composition.
The fundamental elements of the composition of the present invention include 400 to 800 mg of pumpkin seeds, 100 to 200 mg of zinc glycinate, 60 to 600 mg extract of serenoa repens (saw palmetto extract), 200 to 400 mg of pygeum africanum, 100 to 300 mg magnesium, and 300 to 600 I.U. Vitamin E acetate.
In accordance with the composition of the present invention, it is a primary object to provide a dietary supplement having beneficial effects in treating prostate gland disorders.
It is a further object of the present invention to provide a dietary supplement comprised of natural ingredients including pumpkin seeds, zinc glycinate, extract of serenoa repens, pygeum africanum, magnesium and Vitamin E
acetate, which, in combination, yield synergistic effects in treating the symptoms associated with BPH and prostatitis.
It is still a further object of the present invention to provide a dietary supplement comprised of all natural ingredients for treating the symptoms associated with BPH
21 7460~
and prostatitis and which has no adverse side effects.
The fundamental elements of the composition include pumpkin seeds in an amount of between 12.5% to 25% by weight of the composition, extract of serenoa repens (saw palmetto extract) in an amount of between 1.875% to 18.75% by weight of the composition and pygeum africanum in an amount of between 6.25% to 12.55% by weight of the composition. The composition further includes zinc glycinate in an amount of between 3.125% to 6.25% by weight, magnesium in an amount of between 3.125% to 9.375% by weight, and Vitamin E acetate in an amount of between 9.375% to 18.75% by weight of the composition.
The composition preferably includes 25% to 35% by weight Di-Tab, 0.8% to 1.2% by weight Syloid and 0.8% to 1.2% by weight magnesium stearate as excipients.
The composition is preferably provided in the form of tablets or capsules. To do this, the ingredients are first weighed in order to obtain the desired percentage by weight of each of the ingredients to be mixed. Both serenoa repens and pygeum africanum are readily available in liquid or powder form. Liquid is preferred for use in capsules where powder is used for tablets. The ingredients are homogenized directly or in the presence of water by placing the ingredients in a ribbon blender, wherein the ingredients are mixed at medium to high speeds for 20 minutes at a temperature of between 70 to 80 degrees Fahrenheit. The mixture is then placed in dies in a compression machine to mold the mixture into tablets. The compression machine generates a compression of 7 tons, sufficiently compacting the mixture into a uniform, integral tablet. After compression, the tablets are coated with a fine coat of pharmaceutical glaze in order to eliminate dust, prevent the tablets from breaking apart and enhance their appearance.
The coated tablets are then placed in bottles (preferably 60 tablets to a bottle) and labeled for shipping and distribution.
-EXAMPLES OF THE COMPOSITION
Example 1 W%
Pumpkin seeds 18.75 Zinc glycinate 3.125 Magnesium 6.25 Vitamin E acetate 9.375 Extract of serenoa repens 15.625 (saw palmetto extract) Pygeum africanum 9.375 Excipients, including:
Di-Tab Syloid Magnesium stearate 37.5 The recommended dosage for the average adult male is 6 tablets a day which will provide the following amounts of each of the active ingredients of example 1:
Pumpkin seeds - 600 mg Zinc glycinate 100 mg Magnesium 200 mg Vitamin E 300 IU
Saw palmetto extract 500 mg Pygeum africanum 300 mg Example 2 W%
Pumpkin seeds 12.5 Zinc glycinate 6.25 Magnesium 3.125 Vitamin E acetate 18.75 Saw palmetto extract 18.75 Pygeum africanum 6.25 Excipients, including:
Di-Tab Syloid Magnesium stearate 34.375 Example 3 W%
Pumpkin seeds 25.0 Saw palmetto extract 1.875 Pygeum africanum 12.5 Zinc glycinate 6.25 Excipients 45.625 Each of the three examples of the composition were tested with patients suffering from BPH. The efficacy of each of the three examples was determined by measuring 21 746(~8 various parameters includinq prostate-specific antigen concentration (PSA), nicturia, diuria, and maximum urinary flow rate. The results of each of these parameters were compared with known results in the identical parameters for patients treated with individual elements or sub-combinations of the elements of the composition. The overall results ranged between 5 to 8 times greater efficacy of the above three examples compared to the known results of studies using the individual elements of sub-combinations.
The determined efficacy of the composition of the above examples reveals that there is a synergistic effect when combining the elements of the composition within the established range of proportions.
While the composition of the present invention has been set forth in what is believed to be preferred embodiments, it is recognized that departures may be made within the spirit and scope of the following claims which, therefore, should not be limited except within the doctrine of equivalents.
Now that the invention has been described,
ASSOCIATED WITH ENLAR(;~ OF THE PROSTATE GLAND
BACRGROUND OF THE lNvkNllON
Field of the Invention The present invention relates to a dietary supplement, and more particularly, to a dietary supplement for alleviating the symptoms associated with enlargement of the prostate gland.
Description of the Related Art It is well known that many disorders are the result of dietary deficiencies wherein the body is starved of certain vitamins, minerals and other natural elements. Other disorders are simply the result of aging. Disorders due to aging may result if the body produces too much or too little of certain enzymes or hormones, thereby affecting the body's metabolism. Some disorders can be treated or corrected by supplementing missing natural elements which are ordinarily not found in the average diet. Through the use of a daily supplement, supplying these missing vitamins and natural elements, the symptoms of various disorders may improve or disappear entirely.
In men, the prostate gland is the source of several common disorders including prostatitis and benign prostatic hypertrophy, wherein the prostrate gland becomes inflamed or enlarged. Benign prostatic hypertrophy (BPH) occurs naturally in most males over 50 years of age. At this age, the male body begins to transform testosterone (male sex hormone) into dihydroxytestosterone (DHT), at higher levels, within the prostate. This is primarily due to higher levels of the enzyme reductase which causes the conversion of testosterone to DHT. DHT has a tendency to bind to prostatic receptor cells which ultimately results in prostate enlargement. It is usually a benign condition and, thus, in some cases there is no need for surgery. However, enlargement of the prostate gland can cause many uncomfortable and annoying symptoms including:
difficulty in starting to urinate;
increased urge to urinate;
a weak or interrupted stream when urinating;
a feeling that you cannot empty your bladder completely;
a feeling of delay when you start to urinate;
a need to urinate often, especially at night; and frequent or continuous lower back pain.
Nearly 400,000 prostate surgical procedures are performed annually to treat enlarge prostates. Numerous laboratories are conducting research in an attempt to find a cure for BPH (benign prostatic hypertrophy). In 1992, several new drugs were introduced to the market which resulted in reductions of approximately 60%-70% of nicturia, 50% in diuria frequency, and 40% in post mictional residue.
However, some doctors have reported that as many as 15% of patients have complained of impotency after taking these drugs. Additionally, there are side effects which are noted by the FDA, as reported in the January, 1995 issue of U.S.
News and World Report.
There are natural elements which have known benefits in treating enlargement of the prostate gland and prostatitis.
Specifically, it is widely accepted in the field of medicine that zinc has positive effects in reducing an enlarged prostate (see "What Every Man Should Know About His Prostate,~ Monroe E. Greenberger, M.D. and Mary Ellen Siegel MSW, pages 96-105). However, studies have indicated that when zinc is administered orally, it is difficult to reach the prostatic tissue. Therefore, the prostate does not reap the full benefits of the zinc.
Other studies have shown that pygeum africanum extract has definite effects in reducing the size of the prostate (Please refer to Medical Treatment of Benign Prostatic Hypertrophy With the Pygeum Africanum Extract, n R.M. Scarpa, 21~4~Q~
R. Migliari, G. Campus, A. DeLisa, M. Sorgia, M. Usai, E.
Usai, Urology Clinic of the University of Cagliari).
Further, extensive studies carried out in Europe have established that saw palmetto (serenoa repens) effectively reduces the size of the enlarged prostate and restores function. The saw palmetto berry contains an oil composed of sterols and various saturated and unsaturated fatty acids. In Europe, and now in the United States, the purified fat soluble extract from the saw palmetto berry is used medicinally.
Another natural product known to have beneficial effects on the enlarged prostate is pumpkin seeds. While there are no significant medical studies, pumpkin seeds have been used as a folk remedy for centuries. In fact, it is believed that Hungarian gypsies, Ukrainians and Transylvanian's do not suffer from BPH because these cultures eat pumpkin seeds from childhood as part of their daily diet.
Presently, in the United States, most patients suffering from benign prostatic hypertrophy and prostatitis are treated with drugs such as Hytrin~ (Terazosin-HCI), manufactured by Abbott Laboratories, Proscar~, manufactured by Merck and Company, Inc., and Flutamide0. While these drugs have beneficial effects in treating BPH, they have known side effects, including impotency in men. More specifically, Proscar~ is known to be transmitted to females through semen during sexual intercourse, presenting a significant health risk to women who are or could become pregnant. Further, the FDA has reported that Hytrin~ may cause Prioprism, resulting in persistent, painful erections which can permanently damage the penis. The side effects of Flutamide~ include painful swelling of the man's breasts as well as nausea, vomiting and diarrhea.
Summary of the Invention The present invention is directed to a dietary supplement for alleviating the symptoms associated with enlargement of the prostate gland and inflammation of the prostate gland and comprising pumpkin seeds, zinc glycinate, extract of serenoa repens, pygeum africanum, magnesium and Vitamin E acetate. While some of these elements have known benefits to the prostate gland, as stated above, it has been found that when combined in accordance with determined proportionate ranges, the combined ingredients have synergistic effects on reduction of the size of the prostate gland, thereby providing more immediate and dramatic relief to those suffering from the symptoms associated with BPH and prostatitis, without the adverse side effects as experienced with the above-mentioned drugs. The efficacy of the composition was determined by monitoring various parameters including serum prostate-specific antigen (PSA) concentrations of patients over 90 day periods, nicturia, diuria, and urine flow rate. These results were compared to known results in past studies using only one element, or a sub-combination of elements of the composition.
The fundamental elements of the composition of the present invention include 400 to 800 mg of pumpkin seeds, 100 to 200 mg of zinc glycinate, 60 to 600 mg extract of serenoa repens (saw palmetto extract), 200 to 400 mg of pygeum africanum, 100 to 300 mg magnesium, and 300 to 600 I.U. Vitamin E acetate.
In accordance with the composition of the present invention, it is a primary object to provide a dietary supplement having beneficial effects in treating prostate gland disorders.
It is a further object of the present invention to provide a dietary supplement comprised of natural ingredients including pumpkin seeds, zinc glycinate, extract of serenoa repens, pygeum africanum, magnesium and Vitamin E
acetate, which, in combination, yield synergistic effects in treating the symptoms associated with BPH and prostatitis.
It is still a further object of the present invention to provide a dietary supplement comprised of all natural ingredients for treating the symptoms associated with BPH
21 7460~
and prostatitis and which has no adverse side effects.
The fundamental elements of the composition include pumpkin seeds in an amount of between 12.5% to 25% by weight of the composition, extract of serenoa repens (saw palmetto extract) in an amount of between 1.875% to 18.75% by weight of the composition and pygeum africanum in an amount of between 6.25% to 12.55% by weight of the composition. The composition further includes zinc glycinate in an amount of between 3.125% to 6.25% by weight, magnesium in an amount of between 3.125% to 9.375% by weight, and Vitamin E acetate in an amount of between 9.375% to 18.75% by weight of the composition.
The composition preferably includes 25% to 35% by weight Di-Tab, 0.8% to 1.2% by weight Syloid and 0.8% to 1.2% by weight magnesium stearate as excipients.
The composition is preferably provided in the form of tablets or capsules. To do this, the ingredients are first weighed in order to obtain the desired percentage by weight of each of the ingredients to be mixed. Both serenoa repens and pygeum africanum are readily available in liquid or powder form. Liquid is preferred for use in capsules where powder is used for tablets. The ingredients are homogenized directly or in the presence of water by placing the ingredients in a ribbon blender, wherein the ingredients are mixed at medium to high speeds for 20 minutes at a temperature of between 70 to 80 degrees Fahrenheit. The mixture is then placed in dies in a compression machine to mold the mixture into tablets. The compression machine generates a compression of 7 tons, sufficiently compacting the mixture into a uniform, integral tablet. After compression, the tablets are coated with a fine coat of pharmaceutical glaze in order to eliminate dust, prevent the tablets from breaking apart and enhance their appearance.
The coated tablets are then placed in bottles (preferably 60 tablets to a bottle) and labeled for shipping and distribution.
-EXAMPLES OF THE COMPOSITION
Example 1 W%
Pumpkin seeds 18.75 Zinc glycinate 3.125 Magnesium 6.25 Vitamin E acetate 9.375 Extract of serenoa repens 15.625 (saw palmetto extract) Pygeum africanum 9.375 Excipients, including:
Di-Tab Syloid Magnesium stearate 37.5 The recommended dosage for the average adult male is 6 tablets a day which will provide the following amounts of each of the active ingredients of example 1:
Pumpkin seeds - 600 mg Zinc glycinate 100 mg Magnesium 200 mg Vitamin E 300 IU
Saw palmetto extract 500 mg Pygeum africanum 300 mg Example 2 W%
Pumpkin seeds 12.5 Zinc glycinate 6.25 Magnesium 3.125 Vitamin E acetate 18.75 Saw palmetto extract 18.75 Pygeum africanum 6.25 Excipients, including:
Di-Tab Syloid Magnesium stearate 34.375 Example 3 W%
Pumpkin seeds 25.0 Saw palmetto extract 1.875 Pygeum africanum 12.5 Zinc glycinate 6.25 Excipients 45.625 Each of the three examples of the composition were tested with patients suffering from BPH. The efficacy of each of the three examples was determined by measuring 21 746(~8 various parameters includinq prostate-specific antigen concentration (PSA), nicturia, diuria, and maximum urinary flow rate. The results of each of these parameters were compared with known results in the identical parameters for patients treated with individual elements or sub-combinations of the elements of the composition. The overall results ranged between 5 to 8 times greater efficacy of the above three examples compared to the known results of studies using the individual elements of sub-combinations.
The determined efficacy of the composition of the above examples reveals that there is a synergistic effect when combining the elements of the composition within the established range of proportions.
While the composition of the present invention has been set forth in what is believed to be preferred embodiments, it is recognized that departures may be made within the spirit and scope of the following claims which, therefore, should not be limited except within the doctrine of equivalents.
Now that the invention has been described,
Claims (3)
1. A dietary supplement for alleviating the symptoms associated with enlargement of the prostate gland, comprising the following ingredients:
pumpkin seeds in an amount of between 12.50 to 25% by weight of the composition;
extract of serenoa repens in an amount of between 1.875 to 18.75% by weight of the composition;
pygeum africanum in an amount of between 6.25 to 12.5%
by weight of the composition;
zinc glycinate in an amount of between 3.125 to 6.25%
by weight of the composition; and excipients, wherein the amount of ingredients in the dietary supplement totals 100%.
pumpkin seeds in an amount of between 12.50 to 25% by weight of the composition;
extract of serenoa repens in an amount of between 1.875 to 18.75% by weight of the composition;
pygeum africanum in an amount of between 6.25 to 12.5%
by weight of the composition;
zinc glycinate in an amount of between 3.125 to 6.25%
by weight of the composition; and excipients, wherein the amount of ingredients in the dietary supplement totals 100%.
2. A dietary supplement as set forth in claim 1 which further comprises the following ingredients:
magnesium in an amount of between 3.125 to 9.375% by weight of the composition; and vitamin E acetate in an amount of between 9.375 to 18.75% by weight of the composition, wherein the amount of ingredients in the dietary supplement totals 100%.
magnesium in an amount of between 3.125 to 9.375% by weight of the composition; and vitamin E acetate in an amount of between 9.375 to 18.75% by weight of the composition, wherein the amount of ingredients in the dietary supplement totals 100%.
3. A dietary supplement for alleviating the symptoms associated with enlargement of the prostate gland, comprising the following ingredients:
pumpkin seeds in an amount of between 12.5 to 25% by weight of the composition;
zinc glycinate in an amount of between 3.125 to 6.25%
by weight of the composition;
magnesium in an amount of between 3.125 to 9.375% by weight of the composition;
vitamin E acetate in an amount of between 9.375 to 18.75% by weight of the composition;
extract of serenoa repens in an amount of between 1.875 to 18.75% by weight of the composition; and pygeum africanum in an amount of between 6.25 to 12.5%
by weight of the composition.
pumpkin seeds in an amount of between 12.5 to 25% by weight of the composition;
zinc glycinate in an amount of between 3.125 to 6.25%
by weight of the composition;
magnesium in an amount of between 3.125 to 9.375% by weight of the composition;
vitamin E acetate in an amount of between 9.375 to 18.75% by weight of the composition;
extract of serenoa repens in an amount of between 1.875 to 18.75% by weight of the composition; and pygeum africanum in an amount of between 6.25 to 12.5%
by weight of the composition.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/526,992 | 1995-09-12 | ||
| US08/526,992 US5543146A (en) | 1995-01-20 | 1995-09-12 | Dietary supplement for alleviating the symptoms associated with enlargement of the prostate gland |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2174608A1 CA2174608A1 (en) | 1997-03-13 |
| CA2174608C true CA2174608C (en) | 1999-06-22 |
Family
ID=24099664
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002174608A Expired - Fee Related CA2174608C (en) | 1995-09-12 | 1996-04-19 | Dietary supplement for alleviating the symptoms associated with enlargement of the prostate gland |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2174608C (en) |
-
1996
- 1996-04-19 CA CA002174608A patent/CA2174608C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2174608A1 (en) | 1997-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5543146A (en) | Dietary supplement for alleviating the symptoms associated with enlargement of the prostate gland | |
| JP3727538B2 (en) | Prostate compound | |
| Fara et al. | Epidemic of breast enlargement in an Italian school | |
| Mahboubi | Foeniculum vulgare as valuable plant in management of women's health | |
| US9072693B2 (en) | Micronutrient supplement with calcium, vitamin D or calcium and vitamin D combination for premenstrual/menstrual relief | |
| Krause et al. | Systemic effects of vaginally administered estrogen therapy: a review | |
| Oyelami et al. | The use of Kigelia africana in the management of polycystic ovary syndrome (PCOS) | |
| AU2018361636A1 (en) | A dietary composition comprising plant-based sources of fatty acids | |
| CA2174608C (en) | Dietary supplement for alleviating the symptoms associated with enlargement of the prostate gland | |
| WO1997032593A2 (en) | Composition containing iso-flavonoids and lignans | |
| CN101313920A (en) | Application of truffle extract in preparing foods, medicine for treating endocrine dyscrasia diseases | |
| US6245340B1 (en) | Method of improving the immune response and compositions therefor | |
| Siregar et al. | The Effect of Ginger Booking and the Aroma of Lemon Inhalation Therapy Towards Gerdadian Emesis Gravidarum for Pregnant Mothers in Trimester I | |
| KR100542478B1 (en) | Functional health foodstuffs containing phytoestrogens derived from pomegranate | |
| MXPA96001980A (en) | A dietary supplement for alleviating the symptoms associated with enlargement of the prostate gland | |
| JP4583599B2 (en) | Use of Nugari Nuts Oil for the Treatment / Reduction of Onset of Arthritis and Similar Symptoms | |
| CN109275903A (en) | Sexual health food suitable for male and female | |
| US6497890B2 (en) | Anti-wrinkle preparation and method of reducing wrinkles in facial skin and neck | |
| JP2007112782A (en) | Estrogen-increasing composition, estrogen-increasing food, estrogen-increasing medicament, and progesterone-increasing composition | |
| CN111110698A (en) | Method for delaying premature ovarian failure of female by dental pulp mesenchymal stem cells | |
| Woolven | The Smart Woman's Guide to PMS and Pain-Free Periods | |
| Biringer | Common physical discomforts of pregnancy | |
| Sultana et al. | A clinical comparative study & efficacy of polyherbal Unani formulations in subclinical hypothyroidism & overt hypothyroidism (Qillat-E-Ifraz-E-Ghudde Darqiyya) | |
| Nigmatova | Nutritional Obesity in Adolescent Girls Promising Steps in Therapy | |
| KARMA | Table No 22. RASAPANCHAKAS OF MUSTADI GANA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20160419 |